A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.

Maeve Aine LoweryKenneth H YuDavid Paul KelsenJames J HardingJohn S BomalaskiDanielle C GlassmanChristina M CovingtonRobin BrennerEllen HollywoodAdalberto BarbaAmanda JohnstonKay Chia-Wei LiuXiaoxing FengMarinela CapanuGhassan K Abou-AlfaEileen M O'Reilly

Published in: Cancer (2017)

ADI-PEG 20 was well tolerated in combination with gemcitabine and nab-paclitaxel. Activity was observed in previously treated and untreated patients with advanced pancreatic cancer and in patients with ASS1-deficient and -proficient tumors. Cancer 2017;123:4556-4565. © 2017 American Cancer Society.

Keyphrases

papillary thyroid
squamous cell
drug delivery
advanced non small cell lung cancer
locally advanced
lymph node metastasis
squamous cell carcinoma
study protocol
young adults
childhood cancer
epidermal growth factor receptor
rectal cancer
open label